FOCUS on...

Geldanamania!

Heat Shock Proteins play important roles in the regulation of cell growth, cell survival, and oncogenesis. Inhibition of Hsp90 by geldanamycin leads to preferential degradation of a variety of tumor-specific mutated proteins as compared to their non-mutated counterparts in normal cells, which halts tumor genesis. Unfortunately geldanamycin is hepatotoxic, and has a variety of undesirable side-effects at effective concentrations *in vivo*. Therefore, a variety of geldanamycin analogues have been developed in the hopes of eliminating the undesirable effects and creating a viable drug candidate.



Geldanamycin

Geldanamycin

Inhibits HSP90 by binding to its ATP-binding domain (K_d=1.2 μM) and subsequently inhibits HSP90 client proteins. Induces apoptosis in various cell types[1,2]. Cell permeable.

10-1084 1 mg , 5 mg

17-AAG

Semi-synthetic analog of geldanamycin which is less toxic and more stable. Selectively binds to and inhibits HSP90 from tumor cells. Anti-angiogenic activity. Cell permeable.[3-5]

10-1097 1 mg , 5 mg

17-DMAG

Geldanamycin analog that displays superior pharmacological properties. Inhibits HSP90 and induces apoptosis in a variety of tumor cell lines. Inhibits angiogenesis. Cell Permeable.[6,7]

10-1169 1 mg , 5 mg

17-GMP-APA-GA

Geldanamycin analog equipped with linker for coupling to proteins or antibodies for the preparation of immunoconjugates, for example.[8-10]

10-1324 1 mg

Geldanamycin-biotin

Geldanamycin linked to biotin to allow for the affinity purification of HSP-90 and HSP-90 client proteins from a variety of samples.[11]

10-1288 1 mg

References

1. Neckers *et al.* (1999) Invest. New Drugs **17** 361
2. Zang *et al.* (2006) Mol. Cell. Biochem. **281** 111
3. Schulte *et al.* (1998) Cancer Chemother. Pharmacol. **42** 273
4. Kamal *et al.* (2003) Nature **425** 407
5. Kaur *et al.* (2004) Clinical Cancer Res. **10** 4813
6. Glaze *et al.* (2005) Cancer Chemother. Pharmacol., **56** 637
7. Kaur *et al.* (2004) Clin. Cancer Res., **10** 4813
8. Mandler *et al.* (2004) Cancer Res., **64** 1460
9. Mandler *et al.* (2002) Bioconj. Chem., **13** 786
10. Mandler *et al.* (2000) J. Natl. Cancer Inst., **92** 1573
11. Clevenger *et al.* (2004) J. Org. Chem., **69** 437

400 Davis Dr. Suite 600 Plymouth Meeting PA 19462 • sales@focusbiomolecules.com • 610-994-1134 • focusbiomolecules.com

FOCUS BIOMOLECULES